NASDAQ:BIVI BioVie (BIVI) Stock Price, News & Analysis $1.91 +0.06 (+3.24%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.86 -0.05 (-2.62%) As of 10/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioVie Stock (NASDAQ:BIVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioVie alerts:Sign Up Key Stats Today's Range$1.81▼$1.9150-Day Range$1.48▼$2.0152-Week Range$1.42▼$75.00Volume110,250 shsAverage Volume196,655 shsMarket Capitalization$14.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview BioVie Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America. The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit. In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices. Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.AI Generated. May Contain Errors. Read More BioVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreBIVI MarketRank™: BioVie scored higher than 11% of companies evaluated by MarketBeat, and ranked 903rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BioVie.Read more about BioVie's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioVie is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioVie is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioVie has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioVie's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.06% of the float of BioVie has been sold short.Short Interest Ratio / Days to CoverBioVie has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioVie has recently decreased by 15.97%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioVie does not currently pay a dividend.Dividend GrowthBioVie does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.06% of the float of BioVie has been sold short.Short Interest Ratio / Days to CoverBioVie has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioVie has recently decreased by 15.97%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows6 people have added BioVie to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioVie insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.90% of the stock of BioVie is held by insiders.Percentage Held by InstitutionsOnly 4.59% of the stock of BioVie is held by institutions.Read more about BioVie's insider trading history. Receive BIVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIVI Stock News HeadlinesBioVie Inc. (BIVI) Discusses Latest Clinical Advancements, Investment Potential, And Upcoming Data Readouts TranscriptOctober 9, 2025 | seekingalpha.comBioVie Inc. - Special CallOctober 8, 2025 | seekingalpha.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology. | Banyan Hill Publishing (Ad)BioVie to Host Live Investor Webinar and Q&A on Oct. 8September 26, 2025 | globenewswire.comBioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection SyndromesAugust 13, 2025 | globenewswire.comBioVie Inc. Announces Closing of $12 Million Public OfferingAugust 11, 2025 | tmcnet.comBioVie stock dips on pricing $12M securities offeringAugust 8, 2025 | msn.comBioVie Inc. Announces Pricing of $12 Million Public Offering | BIVI Stock NewsAugust 7, 2025 | gurufocus.comSee More Headlines BIVI Stock Analysis - Frequently Asked Questions How have BIVI shares performed this year? BioVie's stock was trading at $20.00 at the start of the year. Since then, BIVI shares have decreased by 90.5% and is now trading at $1.91. How were BioVie's earnings last quarter? BioVie Inc. (NASDAQ:BIVI) announced its quarterly earnings data on Monday, May, 12th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.20) by $1.70. When did BioVie's stock split? BioVie's stock reverse split on the morning of Monday, July 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of BioVie? Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry Co., Ltd. Sponsored GDR (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI). Company Calendar Last Earnings5/12/2025Today10/18/2025Next Earnings (Estimated)11/12/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BIVI CIK1580149 Webbioviepharma.com Phone(775) 888-3162FaxN/AEmployees10Year Founded2013Profitability EPS (Trailing Twelve Months)($79.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-89.02% Return on Assets-75.32% Debt Debt-to-Equity RatioN/A Current Ratio9.10 Quick Ratio9.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.93 per share Price / Book0.19Miscellaneous Outstanding Shares7,540,000Free Float7,467,000Market Cap$14.40 million OptionableNo Data Beta0.71 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BIVI) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.